Ikemoto H, Ito C, Yoshida T, Watanabe K, Mori T, Ohno I, Okada S, Igari J, Arakawa M, Igarashi K, Oguri T, Okada M, Ozaki K, Terai T, Aoki N, Inoue H, Nakadate T, Kitamura N, Sekine O, Suzuki Y, Ando M, Suga M, Sato K, Nakata K, Kusano N
Juntendo University, School of Medicine.
Jpn J Antibiot. 1999 May;52(5):353-97.
The bacteria isolated from the patients with lower respiratory tract infections were collected by institutions located throughout Japan, since 1981. Ikemoto et al. have been investigating susceptibilities of these isolates to various antibacterial agents and antibiotics, and analyzed some characteristics of the patients and isolates from them each year. Results obtained from these investigations are discussed. In these 17 institutions around the entire Japan, 512 strains of presumably etiological bacteria were isolated mainly from the sputa of 440 patients with lower respiratory tract infections during the period from October in 1997 to September in 1998. MICs of various antibacterial agents and antibiotics were determined against 100 strains of Staphylococcus aureus, 81 strains of Streptococcus pneumoniae, 85 strains of Haemophilus influenzae. 71 strains of Pseudomonas aeruginosa (non-mucoid strains), 27 strains of Pseudomonas aeruginosa (mucoid strains), 33 strains of Moraxella subgenus Branhamella catarrhalis, 17 strains of Klebsiella pneumoniae etc., and the susceptibilities of these strains were assessed except for those strains that died during transportation. S. aureus strains for which MICs of oxacillin (MPIPC) were higher than 4 micrograms/ml (methicillin-resistant S. aureus: MRSA) accounted for 55.0%. The frequency of the drug resistant bacteria decreased comparing to the previous year's 67.3%. Arbekacin (ABK) and vancomycin (VCM) showed the most potent activities against MRSA. Imipenem (IPM) and panipenem (PAPM) of carbapenems showed the most potent activities with MIC80S of 0.063 microgram/ml against S. pneumoniae. The frequency of penicillin (PC)-intermediate S. pneumoniae (PISP)+PC-resistant S. pneumoniae (PRSP) had decreased gradually, that is, in 1995 the frequency of it was 40.3%, but that was 30.9% in 1997. Against H. influenzae and M.(B.) catarrhalis, all the drugs showed good activities. But the sensitive strains of them against ceftazidime (CAZ) had decreased in 1997, compared those in 1995 and 1996. Meropenem (MEPM), IPM and tobramycin (TOB) showed the most potent activity against P. aeruginosa (mucoid strains). And TOB and ciprofloxacin (CPFX) showed the most potent activities against P. aeruginosa (non-mucoid strains). All drugs except ampicillin (ABPC) were more active against K. pneumoniae in 1997 than that in 1996. Also, we investigated year to year changes in the characteristics of patients, their respiratory infectious diseases, and the etiology. The examination of age distribution indicated that the proportion of patients with ages over 70 years was 45.5% of all the patients showing a slight increase year by year. About the proportion of diagnosed diseases, not so particular changes were recognized as follows: Bacterial pneumonia and chronic bronchitis were the most frequent with 33.6% and 29.1%, respectively. Number of strains isolated from patients before administration of antibiotics were more than those after administration of them in chronic bronchitis, but these had reversed in bacterial pneumonia. The tendency in bacterial pneumonia had been acknowledged since 1995. The increase of S. aureus and P. aeruginosa (both mucoid and non-mucoid strains) isolated after administration of antibiotics, has suggested the decrease of the susceptibility of these strains against antibiotics. Administration of antibiotics has changed the results of the frequency of isolation of bacterial species. Bacterial isolations before administration of antibiotics were as follows: S. pneumoniae 24.5%, H. influenzae 21.4%, S. aureus 18.4% and P. aeruginosa 12.2%. The frequencies of S. aureus decreased after antibiotics administration over 15 days, but the frequencies of P. aeruginosa was not affected. The frequencies of P. aeruginosa was 47.8% after administration over 15 days. From patients administered antibiotics of penicillins and cephems. S. aureus was mainly detected with 31.7-58.3%, and from patients administere
自1981年起,日本各地的机构收集了从下呼吸道感染患者中分离出的细菌。池本等人一直在研究这些分离菌株对各种抗菌剂和抗生素的敏感性,并每年分析患者及从中分离出的菌株的一些特征。讨论了从这些调查中获得的结果。在全日本的这17家机构中,1997年10月至1998年9月期间,主要从440名下呼吸道感染患者的痰液中分离出512株可能的病原菌。测定了100株金黄色葡萄球菌、81株肺炎链球菌、85株流感嗜血杆菌、71株铜绿假单胞菌(非黏液型菌株)、27株铜绿假单胞菌(黏液型菌株)、33株莫拉克斯菌属卡他莫拉菌、17株肺炎克雷伯菌等对各种抗菌剂和抗生素的最低抑菌浓度(MIC),并评估了这些菌株的敏感性,但不包括运输过程中死亡的菌株。苯唑西林(MPIPC)MIC高于4微克/毫升的金黄色葡萄球菌菌株(耐甲氧西林金黄色葡萄球菌:MRSA)占55.0%。与上一年的67.3%相比,耐药菌的频率有所下降。阿贝卡星(ABK)和万古霉素(VCM)对MRSA显示出最强的活性。碳青霉烯类的亚胺培南(IPM)和美罗培南(MEPM)对肺炎链球菌显示出最强的活性,MIC80为0.063微克/毫升。青霉素(PC)中介肺炎链球菌(PISP)+PC耐药肺炎链球菌(PRSP)的频率逐渐下降,即1995年其频率为40.3%,但1997年为30.9%。对于流感嗜血杆菌和卡他莫拉菌,所有药物均显示出良好的活性。但与1995年和1996年相比。1997年它们对头孢他啶(CAZ)的敏感菌株有所减少。美罗培南(MEPM)、亚胺培南(IPM)和妥布霉素(TOB)对铜绿假单胞菌(黏液型菌株)显示出最强的活性。妥布霉素(TOB)和环丙沙星(CPFX)对铜绿假单胞菌(非黏液型菌株)显示出最强的活性。1997年,除氨苄西林(ABPC)外的所有药物对肺炎克雷伯菌的活性均高于1996年。此外,我们还研究了患者特征、其呼吸道传染病及病因的逐年变化。年龄分布检查表明,70岁以上患者占所有患者的比例为45.5%,且逐年略有增加。关于确诊疾病的比例,未发现特别变化如下:细菌性肺炎和慢性支气管炎最为常见,分别为33.6%和